MedTrace Logo

A Clinical Research of CAR T Cells Targeting CEA Positive Colorectal Cancer (CRC)

NCT04513431 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-08-14

No results posted yet for this study

Summary

The main purpose of this research is to verify the safety of CEA targeted chimeric antigen receptor T cells and to determine the proper dosage of CAR T cells infused.

Conditions

  • Stage III Colorectal Cancer
  • Colorectal Cancer Liver Metastasis

Interventions

BIOLOGICAL

Anti-CEA-CAR T

T cells modified with CEA targeted chimeric antigen receptor.

Sponsors & Collaborators

  • HuaDao (Shanghai) Biomedical Co., Ltd.

    collaborator OTHER

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Ren Zhao, Medical PhD · Ruijin Hospital

  • Mei Wang, Medical PhD · Ruijin Hospital

  • Chen xianze, Medical PhD · Ruijin Hospital

  • Liu Kun, Medical PhD · Ruijin Hospital

  • Shi Yiqing, Medical PhD · Ruijin Hospital

  • Wang Chen, Medical PhD · Ruijin Hospital

  • He Qianyun, Medical PhD · Ruijin Hospital

  • Mao Dongliang, Medical PhD · Ruijin Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-30
Primary Completion
2021-03-30
Completion
2023-08-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04513431 on ClinicalTrials.gov